Citadel Advisors
KIN

Citadel Advisors’s Kindred Biosciences, Inc. KIN Stock Holding History

Citadel Advisors’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,100
Closed -$85K – 14863
2021
Q1 		$85K Buy
+17,100
New +$82.6K ﹤0.01% 12605

Other funds holding KIN

CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Citadel Advisors's KIN Position: Q3 2021 in Review

Citadel Advisors sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 16,369 shares — an estimated $150K sold.

Citadel Advisors first reported a position in KIN in Q1 2014 and held it in 11 quarters. The position peaked at $373K in Q3 2018. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.

  • Citadel Advisors reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Citadel Advisors sold 16,369 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $150K.
  • Citadel Advisors first reported a position in Kindred Biosciences, Inc. in Q1 2014 and held it in 11 quarters.
  • Citadel Advisors's Kindred Biosciences, Inc. position peaked at $373K in Q3 2018.
  • 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.

Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.